Cassava Sciences to Present at Maxim Group’s Conference on Alzheimer’s Disease
18 June 2019 - 10:30PM
Cassava Sciences, Inc. (Nasdaq: SAVA), a clinical-stage
biotechnology company, announced today that Remi Barbier, its
President and CEO, will present at Maxim Group’s conference on
Alzheimer’s disease on Wednesday, June 26th, in New York.
Maxim’s conference for investors, titled “Alzheimer’s Disease –
What’s Next? Treating Alzheimer’s in a Post-Amyloid World”, will be
held at their corporate offices at 405 Lexington Ave in New York.
Cassava Sciences’ presentation for this
conference is now available on the Company’s website under
https://www.cassavasciences.com/company-presentations.
“This conference will bring together leaders
from the research community who share our commitment to
improving outcomes for patients with Alzheimer’s disease,” said
Remi Barbier, President & CEO. “We look forward to presenting
our well-differentiated scientific approach.”
About
PTI-125PTI-125 is an investigational drug
candidate for Alzheimer’s disease. This small molecule drug
has a novel mechanism of action (it does not seek to clear amyloid
out of the brain). Our scientific approach is to stabilize a
critical protein in the brain. PTI-125 has demonstrated both
cognitive improvement and slowing of disease progression in animal
models of disease.
In the second half of 2019, Cassava Sciences
expects to announce results of a Phase 2a study with PTI-125 in
patients with Alzheimer’s disease, after the clinical data are
analyzed.
About Alzheimer's
DiseaseAlzheimer’s disease is a progressive brain disorder
that destroys memory and thinking skills. Eventually, a person with
Alzheimer’s disease may be unable to carry out even simple
tasks. Currently, there are no drug therapies to halt
Alzheimer’s disease, much less reverse its course. Unless effective
treatments are developed soon, Alzheimer’s disease is likely to
become one of the world’s most serious health care
crises.
About Cassava Sciences,
Inc.The mission of Cassava Sciences is to detect and treat
neurodegenerative diseases, such as Alzheimer’s disease. Over
the past ten years, we have combined state-of-the-art technology
with new insights in neurobiology to develop novel solutions for
Alzheimer’s disease. We own worldwide development and commercial
rights to our research programs in Alzheimer’s disease, and related
technology, without royalty obligations to any third-party.
For More Information
Contact:Eric Schoen, Chief Financial OfficerCassava
Sciences, Inc.eschoen@CassavaSciences.com(512) 501-2450
Note Regarding Forward-Looking
Statements: This press release contains forward-looking
statements for purposes of the Private Securities Litigation Reform
Act of 1995 (the "Act"). Cassava Sciences disclaims any
intent or obligation to update these forward-looking statements and
claims the protection of the Safe Harbor for forward-looking
statements contained in the Act. Examples of such statements
include, but are not limited to, statements regarding the timing of
clinical studies and the potential benefits of the Company’s
programs in Alzheimer’s disease, including its ongoing Phase II
program. The Company cautions that forward-looking statements are
inherently uncertain. Such statements are based on management's
current expectations, but actual results may differ materially due
to various factors. Such statements involve risks and
uncertainties, including, but not limited to, those risks and
uncertainties relating to the ability to demonstrate the
specificity, safety, efficacy or potential health benefits of our
product candidates and including those described in the section
entitled “Risk Factors” in Cassava’s Annual Report on Form 10-K for
the year ended December 31, 2018. Existing and prospective
investors are cautioned not to place undue reliance on these
forward-looking statements, which speak only as of the date
hereof. Except as required by law, the Company disclaims any
intention or responsibility for updating or revising any
forward-looking statements contained in this press release.
For further information regarding these and other risks related to
our business, investors should consult our filings with the U.S.
Securities and Exchange Commission (SEC), which are available on
the SEC's website at www.sec.gov.
Cassava Sciences (NASDAQ:SAVA)
Historical Stock Chart
From Apr 2024 to May 2024
Cassava Sciences (NASDAQ:SAVA)
Historical Stock Chart
From May 2023 to May 2024